Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01154114 · ClinicalTrials.gov registry record · Phase 1
Study to Evaluate Darapladib in Moderately Hepatically Impaired Subjects
A Phase 1 study of Atherosclerosis, sponsored by GlaxoSmithKline.
- Completed
- Registry status
- Phase 1
- Development phase
- 24
- Enrollment target
- 2
- Study locations
NCT01154114: Completed Phase 1 study of Atherosclerosis, sponsored by GlaxoSmithKline.
NCT01154114 is a Phase 1 study of Atherosclerosis that has completed, run by GlaxoSmithKline. The registered enrollment target is 24 participants, below the 1,065-participant average among 69 other Atherosclerosis trials with a reported enrollment target (98% lower). The trial reports 2 study locations across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01154114, a Phase 1 study of Atherosclerosis, has completed, sponsored by GlaxoSmithKline.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 24 participants
- Enrollment target
- 2
- Study locations
Study Summary
The purpose of this study is to determine any differences in pharmacokinetic parameters of darapladib when dosed to people with moderate liver disease as compared to when dosed in normal healthy volunteers.
Conditions Studied
Interventions
- DRUG darapladib
Study Locations (2)
Florida
- GSK Investigational Site - Miami
- GSK Investigational Site - Orlando
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 24 participants |
| Start Date | 2010-07-01 |
| Est. Completion | 2010-10-15 |
| Phase | Phase 1 |
What the finished NCT01154114 record still lists
NCT01154114 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 24 participants, a relatively small participant target, below the 1,065-participant average among 69 other Atherosclerosis trials with a reported enrollment target (98% lower).
The record links to 1 condition, with Atherosclerosis appearing as the primary indexed condition, and to 1 intervention - of which darapladib is the first listed.
NCT01154114 reports a single indexed study location in Florida.
Frequently Asked Questions
What is clinical trial NCT01154114 about?
NCT01154114 is a clinical study titled "Study to Evaluate Darapladib in Moderately Hepatically Impaired Subjects". The purpose of this study is to determine any differences in pharmacokinetic parameters of darapladib when dosed to people with moderate liver disease as compared to when dosed in normal healthy volunteers.
What is the current status of trial NCT01154114?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 24 participants. The study started on 2010-07-01. Estimated completion is 2010-10-15.
What conditions does trial NCT01154114 study?
This clinical trial studies the following conditions: Atherosclerosis.
What interventions are being tested in trial NCT01154114?
The interventions under investigation include: darapladib (DRUG).
Who is sponsoring clinical trial NCT01154114?
This trial is sponsored by GlaxoSmithKline, which has 1,345 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT01154114 being conducted?
This trial has 2 study locations across Florida. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Atherosclerosis
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT01154114's enrollment target sits among peer trials
24 67th of 69 higher than 2 of 69 other Atherosclerosis trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Atherosclerosis trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
A Clinical and Histological Analysis of Mesenchymal Stem Cells in Amputation
COMPLETED · Phase 1
-
Indocyanine Green Fluorescence Uptake in Human Carotid Artery Plaque
COMPLETED · Phase 1
-
Single and Multiple Ascending Doses of MEDI6570 in Subjects With Type 2 Diabetes Mellitus
COMPLETED · Phase 1
-
Effect of Tirzepatide on Progression of Coronary Atherosclerosis Using MDCT
RECRUITING · Phase 4
-
Text Education About Cardiovascular Health and HIV (TEACH-HIV)
RECRUITING · NA
-
PET/CT* vs. Cardiac CT for Detecting Coronary Atherosclerotic Disease [*PET: Positron Emission Tomography; CT: Computed Tomography]
RECRUITING · NA
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02331979 · 24 participants · NA
Improving Bladder Function in SCI by Neuromodulation
- NCT03096197 · 24 participants · NA
Exoskeleton and Spinal Cord Stimulation for SCI
- NCT03223922 · 24 participants · NA
Neurocognitive Functioning With Genu-Sparing Whole Brain Radiation Therapy for Brain Metastases
- NCT03326921 · 24 participants · Phase 1
HA-1 T TCR T Cell Immunotherapy for the Treatment of Patients With Relapsed or Refractory Acute Leukemia After Donor Stem Cell Transplant
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI